1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K.

TTSE:4892
569.00
JPY
-12.00
(-2.07%)
5.55BMarket Cap
Nov 13Next Earn
Cyfuse Biomedical K.K.
TSE:4892
(Tokyo Stock Exchange)

Recent

price

569.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
JPY
19.18
98.81
140.38
7.82
6.76
26.24
- -
Revenue per Share
-45.97
19.94
-177.67
-75.42
-108.34
-86.78
- -
Basic EPS, GAAP
-41.05
22.54
-236.87
-74.47
-95.53
-66.16
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
216.16
265.08
484.97
405.8
310.63
286.9
259.83
Book Value per Share
215.38
264.41
484.26
405.24
310.12
286.55
259.55
Tangible Book Value per Share
7
7
3
8
8
9
9
Basic Weighted Avg Shares
137
708
374
61
54
231
- -
Sales/Revenue/Turnover
-270.68
9.96
-113.52
-1,141.24
-1,645.91
-358.52
- -
Operating Margin (%)
33
18
54
38
36
35
- -
Depreciation Expense
-330
143
-474
-589
-872
-764
- -
Net Income, GAAP
- -
1.39
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-239.66
20.18
-126.57
-964.15
-1,602.02
-330.67
- -
Profit Margin (%)
1,945
2,172
3,883
3,321
2,592
3,068
2,645
Working Capital
440
360
363
345
327
642
383
LT Debt
1,549
1,900
3,770
3,203
2,542
2,758
2,622
Total Equity
- -
3.04
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
6.51
- -
- -
- -
- -
- -
Return on Capital (%)
- -
8.29
-16.72
-16.9
-30.36
-28.82
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
468
- -
850
LT Borrowings
336
- -
383
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
10
10
Market Capitalization
6,009
5,893
5,551

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
3,529
- -
3,565
Cash, Cash Equivalents & STI
3,385
- -
3,392
Accounts Receivable, Net
4
- -
3
Inventories
49
- -
74
Total Current Liabilities
578
- -
920
Payables & Accruals
- -
- -
- -
ST Debt
468
- -
850
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.77%
8.47%
Free Cash Flow
- -
-129.21%
-24.28%
Net Income, GAAP
- -
-103.02%
-12.43%
Sales/Revenue/Turnover
- -
119.54%
324.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
7
- -
- -
54
2025
- -
- -
- -
- -
231
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-28.38
-27.76
- -
- -
-108.34
2025
- -
- -
- -
- -
-86.78
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Cyfuse Biomedical K.K. (4892.T) develops, manufactures and sells regenerative medicine products and 3D bioprinting systems in Japan. The company offers Bio 3D Printers including regenova, a robotic system for fabricating 3D cellular structures from cell spheroids arranged in needle arrays; and S-PIKE, a next-generation printer for scaffold-free tissue engineering applicable to cartilage, bone, blood vessels, nerves and drug discovery models; alongside functional cellular devices as tools for pharmaceutical research and contract development of cell products. Founded in 2010 and headquartered in Minato-ku, Tokyo, with an additional office in Fukuoka, the firm targets healthcare providers, pharmaceutical companies and research institutions through its proprietary scaffold-free 3D printing platform. Recent developments include a 2025 joint announcement with PHC Corporation on innovative 3D cell product production technology for commercialization; business partnership with Marubeni Corporation for global expansion of S-PIKE; and sales alliance with Sysmex Corporation to market the printer; building on the 2023 strategic alliance with PHC to accelerate regenerative medicine pipelines.